



CKET NO.: PHRM-0303

PATENT

0300  
H.A.  
attachment

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark E. Gurney et al.

Serial No.: 09/767,088

Group Art Unit: Not Yet Assigned

Filing Date: January 22, 2001


Examiner: Not Yet Assigned

For: **TRANSGENIC MOUSE MODEL OF HUMAN NEURODEGENERATIVE DISEASE**

DATE OF DEPOSIT:

April 30, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

  
TYPED NAME: Robin S. Quartin  
REGISTRATION NO.: 45,028

Assistant Commissioner for Patents  
Washington DC 20231

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).



In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- ☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were

previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:

- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date:

*April 30, 2001*



**Robin S. Quartin**

Registration No. 45,028

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439




#4

Sheet 1 of 3

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>PHRM-0303</b>	Serial No. <b>09/767,088</b>
		Applicant <b>Mark E. Gurney et al.</b>	
		Filing Date <b>January 22, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AA</b>	Arawaka, S. et al., "The tau mutation (val337met) disrupts cytoskeletal networks of microtubules", Neuroreport, (1999) 10:993-997	
	<b>AB</b>	Brion, J.P. et al., "Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease", Am. J. Pathol., (1999), 154:255-270	
	<b>AC</b>	Brownlees, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3 $\beta$ transgenes", Neuroreport, (1997), 8:3251-3255	
	<b>AD</b>	Clark, L.N., et al., "Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17", Proc. Natl. Acad. Sci. USA, (1998), 95: 13103-13107	
	<b>AE</b>	Dayanandan, R. et al., "Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation", FEBS Lett., (1999), 446: 228-232	
	<b>AF</b>	Dumanchin, C., et al., "Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism", Hum. Mol. Genet., (1998), 7:1825-1829	
	<b>AG</b>	Games, D. et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein", Nature, (1995), 373:523-527	
	<b>AH</b>	Goedert, M. et al., "Tau mutations cause frontotemporal dementias", Neuron, (1998), 21:955-958	
	<b>AI</b>	Goedert, M. et al., "Filamentous nerve cell inclusions in neurodegenerative diseases", Curr. Opin. Neurobiol., (1998), 8:619-632	
	<b>AJ</b>	Götz, J., et al., "Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform", EMBO J., (1995), 14:1304-1313	
	<b>AK</b>	Gurney, M.E. et al., "Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis", Ann. Neurol., (1996), 39:147-157	
	<b>AL</b>	Gurney, M.E. et al., "Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation", Science, (1994), 264:1772-1775	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>PHRM-0303</b>	Serial No. <b>09/767,088</b>
		Applicant <b>Mark E. Gurney et al.</b>	
		Filing Date <b>January 22, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AM</b>	Hasegawa, M. et al., "Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly", FEBS Lett., (1998), 437:207-210	
	<b>AN</b>	Hasegawa, M., et al., "FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10", FEBS Lett., 1999, 443:93-96	
	<b>AO</b>	Hong, M. et al., "Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17", Science, (1998), 282:1914-1917	
	<b>AP</b>	Hutton, M. et al., "Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17", Nature, (1998), 393:702-705	
	<b>AQ</b>	Hsiao, K.K., "From prion diseases to Alzheimer's disease", J. Neural. Transm. Suppl., (1997), 49:135-144	
	<b>AR</b>	Iijima, M. et al., "A distinct familial presenile dementia with a novel missense mutation in the tau gene", Neuroreport, (1999), 10:497-501	
	<b>AS</b>	James, N.D. et al., "Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase Mos", Neurobiol. Aging, (1996), 17:235-241	
	<b>AT</b>	Moechars, D. et al., "Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain", Biol. Chem., (1999), 274:6483-6492	
	<b>AU</b>	Nacharaju, P. et al., "Accelerated filament formation from tau protein with specific FTDP-17 missense mutations", FEBS Lett., (1999), 447:195-199	
	<b>AV</b>	Poorkaj, P. et al., "Tau is a candidate gene for chromosome 17 frontotemporal dementia", Ann. Neurol., (1998), 43:815-825	
	<b>AW</b>	Rizzu, P. et al., "High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands", Am. J. Hum. Genet., (1999), 64:414-421	
	<b>AX</b>	Spillantini, M.G. et al., "Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles", Acta Neuropathol., (1996), 92:42-48	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>PHRM-0303</b>	Serial No. <b>09/767,088</b>
		Applicant <b>Mark E. Gurney et al.</b>	
		Filing Date <b>January 22, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AY</b>	Spillantini, M.G. et al., "Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments", Proc. Natl. Acad. Sci. USA, (1997), 94:4113-4118	
	<b>AZ</b>	Spillantini, M.G. et al., "Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau", Am. J. Pathol., (1998), 153:1359-1363	
	<b>BA</b>	Spillantini, M.G. et al., "Mutation in the tau gene in familial multiple system tauopathy with presenile dementia", Proc. Natl. Acad. Sci. USA, (1998), 95:7737-7741	
	<b>BB</b>	Spillantini M.G. et al., "Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies", Brain Pathol., (1998), 8:387-402	
	<b>BC</b>	Spillantini, M.G. et al., "Tau protein pathology in neurodegenerative diseases", Trends Neurosci., (1998), 21:428-433	
	<b>BD</b>	Sturchler-Pierrat, C. et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology", Proc. Natl. Acad. Sci. USA, (1997), 94:13287-13292	
	<b>BE</b>	Tolnay, M. et al., "Tau protein pathology in Alzheimer's disease and related disorders", Neuropathol. Appl. Neurobiol., (1999), 3:171-187	
	<b>BF</b>	Wong, P.C. et al., "An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria", Neuron, (1995), 14:1105-1116	
	<b>BG</b>	Zehr, C. et al., "Production and characterization of tau transgenic mice", Soc. Neurosci., (1999), 25:(A)447.1	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	